MedTrace Logo

Unravelling Intestinal Fibrosis in Ulcerative Colitis

NCT06604273 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-09-19

No results posted yet for this study

Summary

The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET/CT imaging

Conditions

  • Ulcerative Colitis (UC)
  • Inflammatory Bowel Disease (IBD)
  • Fibroblast Activation Protein Inhibitor

Interventions

DIAGNOSTIC_TEST

Fibroblast Activation Protein Inhibitor

PET CT imaging using the fibroblast activation protein inhibitor tracer

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Mark Lowenberg, MD PhD · Amsterdam University Medical Centers

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-03
Primary Completion
2025-10-03
Completion
2026-04-03

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06604273 on ClinicalTrials.gov